debrisoquin has been researched along with Body Weight in 7 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Debrisoquin was administered twice daily at the dose of 2." | 1.26 | The cardiovascular effects of the antihypertensive drug debrisoquin: A contribution to the pharmacology of chronic treatment. II. Eight-week administration to dogs. ( Cavero, I; Gerold, M; Haeusler, G; Saner, A, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danhof, M | 1 |
| Idle, JR | 1 |
| Teunissen, MW | 1 |
| Sloan, TP | 1 |
| Breimer, DD | 1 |
| Smith, RL | 1 |
| Lorez, HP | 2 |
| Kettler, R | 2 |
| Flammer, J | 1 |
| Weidmann, P | 1 |
| Glück, Z | 1 |
| Ziegler, WH | 1 |
| Reubi, FC | 1 |
| Gerold, M | 1 |
| Cavero, I | 1 |
| Saner, A | 1 |
| Haeusler, G | 2 |
| Adi, FC | 1 |
| Eze, CJ | 1 |
| Anwunah, A | 1 |
| Vincent-Viry, M | 1 |
| Deshayes, S | 1 |
| Mothe, O | 1 |
| Siest, G | 1 |
| Galteau, MM | 1 |
| Bartholini, G | 1 |
| Tranzer, JP | 1 |
1 trial available for debrisoquin and Body Weight
| Article | Year |
|---|---|
Comparison of debrisoquine and guanethidine in treatment of hypertension.
Topics: Administration, Oral; Adult; Body Weight; Chronic Disease; Debrisoquin; Economics, Medical; Ejaculat | 1975 |
6 other studies available for debrisoquin and Body Weight
| Article | Year |
|---|---|
Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Topics: Aging; Antipyrine; Body Weight; Debrisoquin; Female; Half-Life; Humans; Hydroxylation; Isoquinolines | 1981 |
Absence of degeneration of adrenergic neurones after prolonged treatment of newborn rats with debrisoquin.
Topics: Animals; Animals, Newborn; Axons; Body Weight; Catecholamines; Debrisoquin; Depression, Chemical; Do | 1975 |
Cardiovascular and endocrine profile of adrenergic neurone blockade in normal and hypertensive man.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Volume; Body Weight; Debrisoquin; Female; Hemodynami | 1979 |
The cardiovascular effects of the antihypertensive drug debrisoquin: A contribution to the pharmacology of chronic treatment. II. Eight-week administration to dogs.
Topics: Anesthesia; Animals; Blood Pressure; Body Weight; Cardiovascular System; Debrisoquin; Dogs; Drug Tol | 1978 |
Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
Topics: Animals; Body Weight; Debrisoquin; Female; Hydroxylation; In Vitro Techniques; Indicators and Reagen | 1988 |
Absence of degeneration of adrenergic neurons after prolonged treatment with debrisoquin.
Topics: Animals; Antihypertensive Agents; Body Weight; Debrisoquin; Dopamine beta-Hydroxylase; Ganglia; Gang | 1974 |